|Bid||4.6800 x 900|
|Ask||5.1000 x 800|
|Day's Range||4.7500 - 4.9500|
|52 Week Range||4.0700 - 13.0000|
|Beta (5Y Monthly)||0.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
What happened Shares of the Swiss biotech AC Immune (NASDAQ: ACIU) lost over 42% of their value in pre-market trading Wednesday morning. The biotech's stock is crashing today in response to the news that its experimental Alzheimer's disease (AD) drug semorinemab failed to meet the primary endpoint of a midstage trial dubbed Tauriel.